209 related articles for article (PubMed ID: 36604142)
1. MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors.
Ye Z; Chen H; Ji S; Hu Y; Lou X; Zhang W; Jing D; Fan G; Zhang Y; Chen X; Zhuo Q; Chen J; Xu X; Yu X; Xu J; Qin Y; Gao H
Acta Biochim Biophys Sin (Shanghai); 2022 Nov; 54(11):1599-1609. PubMed ID: 36604142
[TBL] [Abstract][Full Text] [Related]
2. MEN1 Degradation Induced by Neddylation and the CUL4B-DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression.
Xu J; Ye Z; Zhuo Q; Gao H; Qin Y; Lou X; Zhang W; Wang F; Wang Y; Jing D; Fan G; Zhang Y; Chen X; Chen J; Xu X; Yu X; Ji S
Cancer Res; 2023 Jul; 83(13):2226-2247. PubMed ID: 36939378
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1.
Marini F; Giusti F; Tonelli F; Brandi ML
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919851
[TBL] [Abstract][Full Text] [Related]
4. G protein-coupled estrogen receptor activates PI3K/AKT/mTOR signaling to suppress ferroptosis via SREBP1/SCD1-mediated lipogenesis.
Chen J; Zhao R; Wang Y; Xiao H; Lin W; Diao M; He S; Mei P; Liao Y
Mol Med; 2024 Feb; 30(1):28. PubMed ID: 38383297
[TBL] [Abstract][Full Text] [Related]
5. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.
Chou WC; Lin PH; Yeh YC; Shyr YM; Fang WL; Wang SE; Liu CY; Chang PM; Chen MH; Hung YP; Li CP; Chao Y; Chen MH
Int J Biol Sci; 2016; 12(12):1523-1532. PubMed ID: 27994516
[No Abstract] [Full Text] [Related]
6. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis.
Yi J; Zhu J; Wu J; Thompson CB; Jiang X
Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31189-31197. PubMed ID: 33229547
[TBL] [Abstract][Full Text] [Related]
7. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
[TBL] [Abstract][Full Text] [Related]
8. Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors: New Therapeutic Approaches.
Stevenson M; Lines KE; Thakker RV
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):525-548. PubMed ID: 30098714
[TBL] [Abstract][Full Text] [Related]
9. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
Maxwell JE; Sherman SK; Howe JR
Clin Cancer Res; 2016 Oct; 22(20):5022-5029. PubMed ID: 27742788
[TBL] [Abstract][Full Text] [Related]
10. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
Chamberlain CE; German MS; Yang K; Wang J; VanBrocklin H; Regan M; Shokat KM; Ducker GS; Kim GE; Hann B; Donner DB; Warren RS; Venook AP; Bergsland EK; Lee D; Wang Y; Nakakura EK
Mol Cancer Ther; 2018 Dec; 17(12):2702-2709. PubMed ID: 30254185
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of ZNF488 supports pancreatic cancer cell proliferation and tumorigenesis through inhibition of ferroptosis via regulating SCD1-mediated unsaturated fatty acid metabolism.
Xiao Q; Lan Z; Zhang S; Ren H; Wang S; Wang P; Feng L; Li D; Wang C; Bai X; Zhang J
Biol Direct; 2023 Nov; 18(1):77. PubMed ID: 37986084
[TBL] [Abstract][Full Text] [Related]
12. Multiple Endocrine Neoplasia Type 1 Syndrome Pancreatic Neuroendocrine Tumor Genotype/Phenotype: Is There Any Advance on Predicting or Preventing?
Ramamoorthy B; Nilubol N
Surg Oncol Clin N Am; 2023 Apr; 32(2):315-325. PubMed ID: 36925188
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors.
Nuñez JE; Donadio M; Filho DR; Rego JF; Barros M; Formiga MN; Lopez R; Riechelmann R
J Gastrointest Oncol; 2019 Aug; 10(4):645-651. PubMed ID: 31392045
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA KB-1460A1.5 promotes ferroptosis by inhibiting mTOR/SREBP-1/SCD1-mediated polyunsaturated fatty acid desaturation in glioma.
Xu L; Wen B; Wu Q; Lu S; Liao J; Mo L; Li Q; Tong X; Yan H
Carcinogenesis; 2024 Feb; ():. PubMed ID: 38422369
[TBL] [Abstract][Full Text] [Related]
15. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
Jiao Y; Shi C; Edil BH; de Wilde RF; Klimstra DS; Maitra A; Schulick RD; Tang LH; Wolfgang CL; Choti MA; Velculescu VE; Diaz LA; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N
Science; 2011 Mar; 331(6021):1199-203. PubMed ID: 21252315
[TBL] [Abstract][Full Text] [Related]
16. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis.
Pieterman CR; Conemans EB; Dreijerink KM; de Laat JM; Timmers HT; Vriens MR; Valk GD
Endocr Relat Cancer; 2014 Jun; 21(3):R121-42. PubMed ID: 24389729
[TBL] [Abstract][Full Text] [Related]
17. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
[TBL] [Abstract][Full Text] [Related]
18. Genetics of Pancreatic Neuroendocrine Tumors.
Mohindroo C; McAllister F; De Jesus-Acosta A
Hematol Oncol Clin North Am; 2022 Oct; 36(5):1033-1051. PubMed ID: 36154786
[TBL] [Abstract][Full Text] [Related]
19. Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration.
Razmara M; Monazzam A; Skogseid B
Cell Commun Signal; 2018 Oct; 16(1):64. PubMed ID: 30285764
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors.
Modali SD; Parekh VI; Kebebew E; Agarwal SK
Mol Endocrinol; 2015 Feb; 29(2):224-37. PubMed ID: 25565142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
